Sunshine Biopharma Inc.
SBFM Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025
Revenue
Total sales reported in the income statement.
$36.3M
4.1%
vs prior year
Operating margin
Operating income as a share of revenue.
−17.2%
0.5 pts
Net income
Profit after all expenses, interest and tax.
−$6.0M
Free cash flow
Cash from operations minus capital spending.
−$5.5M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
—
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
What Sunshine Biopharma Inc. does
No business description yet.
- Legal name
- Sunshine Biopharma Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 3, 2026
- Accession · CIK
- 0001683168-26-002644
0001402328
Revenue and margins
Sunshine Biopharma Inc. had $36.3M of revenue in fiscal 2025, up 4.1% on the year before.
FY16
Revenue $0.0M
FY17
Revenue $0.0M
FY18
Revenue $0.0M
FY19
Revenue $0.0M
FY20
Revenue $0.1M
FY21
Revenue $0.2M
FY22
Revenue $4.3M
FY23
Revenue $24.1M
FY24
Revenue $34.9M
FY25
Revenue $36.3M
Q3 '23
Revenue $6.0M
Q4 '23
Revenue $7.7M
Q1 '24
Revenue $7.5M
Q2 '24
Revenue $9.3M
Q3 '24
Revenue $8.4M
Q4 '24
Revenue $9.6M
Q1 '25
Revenue $8.9M
Q2 '25
Revenue $9.4M
Q3 '25
Revenue $9.4M
Q4 '25
Revenue $8.6M
Q1 '26
Revenue $8.1M
Q2 '26
Revenue $9.3M
FY16
Gross —
Operating —
Net —
FCF —
FY17
Gross —
Operating —
Net —
FCF —
FY18
Gross —
Operating —
Net —
FCF —
FY19
Gross 47.9%
Operating −3,040.8%
Net −7,868.7%
FCF −2,354.0%
FY20
Gross 63.9%
Operating −808.0%
Net −3,899.3%
FCF −922.3%
FY21
Gross 48.4%
Operating −1,068.3%
Net −5,445.0%
FCF −800.8%
FY22
Gross 39.0%
Operating −621.3%
Net −615.4%
FCF −125.2%
FY23
Gross 34.6%
Operating −19.9%
Net −18.7%
FCF −36.8%
FY24
Gross 30.6%
Operating −16.7%
Net −14.7%
FCF −40.7%
FY25
Gross 33.8%
Operating −17.2%
Net −16.5%
FCF −15.2%
Gross
Operating
Net
FCF
Q3 '23
Gross 33.4%
Operating −13.1%
Net −10.9%
FCF −7.8%
Q4 '23
Gross 33.4%
Operating −15.5%
Net −16.3%
FCF −30.0%
Q1 '24
Gross 31.2%
Operating −17.9%
Net −17.0%
FCF −43.1%
Q2 '24
Gross 25.3%
Operating −13.6%
Net −5.3%
FCF −59.7%
Q3 '24
Gross 34.0%
Operating −13.1%
Net −14.2%
FCF −22.2%
Q4 '24
Gross 32.2%
Operating −21.2%
Net −22.5%
FCF −36.6%
Q1 '25
Gross 30.7%
Operating −14.6%
Net −13.3%
FCF −19.1%
Q2 '25
Gross 36.4%
Operating −21.8%
Net −18.8%
FCF −15.2%
Q3 '25
Gross 32.6%
Operating −11.5%
Net −9.4%
FCF −8.0%
Q4 '25
Gross 35.3%
Operating −20.9%
Net −25.0%
FCF −18.8%
Q1 '26
Gross 27.0%
Operating −17.3%
Net −15.4%
FCF −25.7%
Q2 '26
Gross 26.2%
Operating −17.4%
Net −16.9%
FCF −10.0%
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY16
Net income −$3.5M
FY17
Net income −$1.0M
FY18
Net income −$2.2M
FY19
Net income −$1.7M
FY20
Net income −$2.8M
FY21
Net income −$12.4M
FY22
Net income −$26.7M
FY23
Net income −$4.5M
FY24
Net income −$5.1M
FY25
Net income −$6.0M
Q3 '23
Net income −$0.7M
Q4 '23
Net income −$1.3M
Q1 '24
Net income −$1.3M
Q2 '24
Net income −$0.5M
Q3 '24
Net income −$1.2M
Q4 '24
Net income −$2.2M
Q1 '25
Net income −$1.2M
Q2 '25
Net income −$1.8M
Q3 '25
Net income −$0.9M
Q4 '25
Net income −$2.1M
Q1 '26
Net income −$1.2M
Q2 '26
Net income −$1.6M
FY16
Diluted EPS —
FY17
Diluted EPS —
FY18
Diluted EPS —
FY19
Diluted EPS —
FY20
Diluted EPS —
FY21
Diluted EPS −$4.76
FY22
Diluted EPS −$1.76
FY23
Diluted EPS −$351.36
FY24
Diluted EPS −$7.32
FY25
Diluted EPS —
Q3 '23
Diluted EPS —
Q4 '23
Diluted EPS —
Q1 '24
Diluted EPS −$2.00
Q2 '24
Diluted EPS −$43.48
Q3 '24
Diluted EPS —
Q4 '24
Diluted EPS —
Q1 '25
Diluted EPS −$0.44
Q2 '25
Diluted EPS −$0.82
Q3 '25
Diluted EPS —
Q4 '25
Diluted EPS —
Q1 '26
Diluted EPS —
Q2 '26
Diluted EPS —
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY16
Return on capital —
Return on equity —
Return on assets −5,429.7%
FY17
Return on capital —
Return on equity —
Return on assets −646.3%
FY18
Return on capital —
Return on equity —
Return on assets −307.1%
FY19
Return on capital —
Return on equity —
Return on assets −266.8%
FY20
Return on capital —
Return on equity —
Return on assets −486.9%
FY21
Return on capital —
Return on equity —
Return on assets −765.7%
FY22
Return on capital —
Return on equity −244.9%
Return on assets −170.1%
FY23
Return on capital —
Return on equity −21.0%
Return on assets −15.9%
FY24
Return on capital —
Return on equity −23.0%
Return on assets −17.7%
FY25
Return on capital —
Return on equity −25.7%
Return on assets −19.7%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$5.5M in fiscal 2025, −15.2% of revenue. Cash from operations minus capital spending.
FY16
Free cash flow −$0.3M
FY17
Free cash flow −$0.5M
FY18
Free cash flow −$0.5M
FY19
Free cash flow −$0.5M
FY20
Free cash flow −$0.7M
FY21
Free cash flow −$1.8M
FY22
Free cash flow −$5.4M
FY23
Free cash flow −$8.9M
FY24
Free cash flow −$14.2M
FY25
Free cash flow −$5.5M
Q3 '23
Free cash flow −$0.5M
Q4 '23
Free cash flow −$2.3M
Q1 '24
Free cash flow −$3.2M
Q2 '24
Free cash flow −$5.6M
Q3 '24
Free cash flow −$1.9M
Q4 '24
Free cash flow −$3.5M
Q1 '25
Free cash flow −$1.7M
Q2 '25
Free cash flow −$1.4M
Q3 '25
Free cash flow −$0.8M
Q4 '25
Free cash flow −$1.6M
Q1 '26
Free cash flow −$2.1M
Q2 '26
Free cash flow −$0.9M
FY16
Cash from operations −$0.3M
Capital spending $0.0M
FY17
Cash from operations −$0.5M
Capital spending $0.0M
FY18
Cash from operations −$0.5M
Capital spending $0.0M
FY19
Cash from operations −$0.5M
Capital spending $0.0M
FY20
Cash from operations −$0.7M
Capital spending $0.0M
FY21
Cash from operations −$1.8M
Capital spending $0.0M
FY22
Cash from operations −$5.2M
Capital spending $0.2M
FY23
Cash from operations −$8.8M
Capital spending $0.1M
FY24
Cash from operations −$12.5M
Capital spending $1.7M
FY25
Cash from operations −$5.3M
Capital spending $0.2M
Cash from operations
Capital spending
Q3 '23
Cash from operations −$0.5M
Capital spending $0.0M
Q4 '23
Cash from operations −$2.7M
Capital spending −$0.4M
Q1 '24
Cash from operations −$3.2M
Capital spending $0.1M
Q2 '24
Cash from operations −$4.6M
Capital spending $1.0M
Q3 '24
Cash from operations −$1.4M
Capital spending $0.5M
Q4 '24
Cash from operations −$3.4M
Capital spending $0.1M
Q1 '25
Cash from operations −$1.7M
Capital spending $0.0M
Q2 '25
Cash from operations −$1.3M
Capital spending $0.2M
Q3 '25
Cash from operations −$0.7M
Capital spending $0.0M
Q4 '25
Cash from operations −$1.6M
Capital spending −$0.0M
Q1 '26
Cash from operations −$2.1M
Capital spending $0.0M
Q2 '26
Cash from operations −$0.9M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
Sunshine Biopharma Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 0.0%.
FY16
Dividends —
Buybacks —
FY17
Dividends —
Buybacks —
FY18
Dividends —
Buybacks —
FY19
Dividends —
Buybacks —
FY20
Dividends —
Buybacks —
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks $0.5M
FY24
Dividends —
Buybacks $3.1M
FY25
Dividends —
Buybacks $0.0M
Dividends
Buybacks
Q3 '23
Dividends —
Buybacks —
Q4 '23
Dividends —
Buybacks $0.0M
Q1 '24
Dividends —
Buybacks $3.1M
Q2 '24
Dividends —
Buybacks $0.0M
Q3 '24
Dividends —
Buybacks $0.0M
Q4 '24
Dividends —
Buybacks $0.0M
Q1 '25
Dividends —
Buybacks $0.0M
Q2 '25
Dividends —
Buybacks $0.0M
Q3 '25
Dividends —
Buybacks $0.0M
Q4 '25
Dividends —
Buybacks $0.0M
Q1 '26
Dividends —
Buybacks —
Q2 '26
Dividends —
Buybacks —
Dividends
Buybacks
FY16
Diluted shares —
FY17
Diluted shares —
FY18
Diluted shares —
FY19
Diluted shares —
FY20
Diluted shares —
FY21
Diluted shares 0.00B
FY22
Diluted shares 0.02B
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.00B
FY25
Diluted shares —
Balance sheet
Cash, debt and the ratios that show how comfortably Sunshine Biopharma Inc. can carry it.
FY16
Cash $0.1M
Debt —
FY17
Cash $0.1M
Debt —
FY18
Cash $0.1M
Debt —
FY19
Cash $0.0M
Debt —
FY20
Cash $1.0M
Debt $0.9M
FY21
Cash $2.0M
Debt —
FY22
Cash $21.8M
Debt —
FY23
Cash $16.3M
Debt —
FY24
Cash $9.7M
Debt —
FY25
Cash $9.1M
Debt —
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.0M | $21.8M | $16.3M | $9.7M | $9.1M |
| Interest coverage | −7.4x | −685.3x | −34.9x | −660.5x | — |
| Current ratio | 24.1x | 3.9x | 4.5x | 4.1x | 4.2x |
| Quick ratio | 22.9x | 3.5x | 3.5x | 2.3x | 2.1x |
| Total assets | $2.2M | $29.2M | $27.3M | $30.6M | $30.1M |
| Total liabilities | $2.0M | $7.6M | $6.1M | $7.1M | $7.0M |
| Shareholders' equity | $0.2M | $21.6M | $21.2M | $23.5M | $23.0M |
| Net debt (− = net cash) | — | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✓ | ✕ | ✓ | ✕ | ✓ | ✓ | ✕ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✕ | ✕ | ✓ |
| Debt fell relative to assets | — | — | — | — | — | — | — | — | — | — |
| Current ratio rose | — | ✕ | ✓ | ✕ | ✓ | ✓ | ✕ | ✓ | ✕ | ✓ |
| Share count didn't rise | — | — | — | — | — | — | ✕ | ✓ | ✕ | — |
| Gross margin rose | — | — | — | — | ✓ | ✕ | ✕ | ✕ | ✕ | ✓ |
| Revenue rose relative to assets | — | ✕ | ✕ | ✓ | ✕ | ✓ | ✓ | ✓ | ✓ | ✓ |
| F-score | — / 3 | — / 6 | — / 6 | — / 6 | 4 / 7 | 3 / 7 | 3 / 8 | 4 / 8 | 1 / 8 | 4 / 7 |
| Accruals ratio | −4,941.8% | −308.6% | −234.1% | −187.1% | −371.9% | −653.1% | −136.7% | 15.1% | 25.5% | −2.1% |
| Altman Z'' | −763.11 | −211.65 | −50.64 | −675.60 | −67.41 | −49.39 | −5.27 | −0.53 | −0.93 | −1.63 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.2M | $4.3M | $24.1M | $34.9M | $36.3M |
| Gross profit | — | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $1.7M | $8.3M | $10.7M | $12.3M |
| Research and development | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.7M | $0.8M | $1.9M | $0.9M | $0.6M |
| Operating income | −$1.0M | −$0.9M | −$1.2M | −$0.6M | −$0.6M | −$2.4M | −$27.0M | −$4.8M | −$5.8M | −$6.2M |
| Interest expense | $0.0M | $0.1M | $0.1M | $0.1M | $0.2M | $0.3M | $0.0M | $0.1M | $0.0M | $0.0M |
| Pretax income | — | — | −$2.1M | −$1.1M | −$2.8M | −$12.4M | −$26.5M | −$4.1M | −$5.4M | −$6.0M |
| Income tax | — | — | — | — | $0.0M | $0.0M | $0.2M | $0.4M | −$0.2M | $0.0M |
| Net income | −$3.5M | −$1.0M | −$2.2M | −$1.7M | −$2.8M | −$12.4M | −$26.7M | −$4.5M | −$5.1M | −$6.0M |
| Net income to common | −$3.5M | −$1.0M | −$2.2M | −$1.7M | −$2.8M | −$12.4M | — | — | −$5.1M | −$6.0M |
| Diluted EPS | — | — | — | — | — | −$4.76 | −$1.76 | −$351.36 | −$7.32 | — |
| Diluted shares | — | — | — | — | — | 0.00B | 0.02B | 0.00B | 0.00B | — |
| Cash flow | ||||||||||
| Cash from operations | −$0.3M | −$0.5M | −$0.5M | −$0.5M | −$0.7M | −$1.8M | −$5.2M | −$8.8M | −$12.5M | −$5.3M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.2M | $0.1M | $1.7M | $0.2M |
| Free cash flow | −$0.3M | −$0.5M | −$0.5M | −$0.5M | −$0.7M | −$1.8M | −$5.4M | −$8.9M | −$14.2M | −$5.5M |
| Depreciation and amortization | $0.1M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.2M | $0.3M |
| Stock-based compensation | $0.5M | $0.5M | $0.8M | $0.3M | $0.3M | — | — | — | — | — |
| Share buybacks | — | — | — | — | — | — | — | $0.5M | $3.1M | $0.0M |
| Dividends and buybacks | — | — | — | — | — | — | — | $0.5M | $3.1M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.1M | $0.1M | $0.1M | $0.0M | $1.0M | $2.0M | $21.8M | $16.3M | $9.7M | $9.1M |
| Total debt | — | — | — | — | $0.9M | — | — | — | — | — |
| Current assets | $0.1M | $0.1M | $1.1M | $0.1M | $1.0M | $2.2M | $27.3M | $24.9M | $26.0M | $26.9M |
| Current liabilities | $0.3M | $0.8M | $0.9M | $0.8M | $1.1M | $0.1M | $6.9M | $5.6M | $6.3M | $6.4M |
| Inventory | — | — | $0.0M | $0.0M | $0.0M | $0.1M | $3.3M | $5.7M | $11.3M | $13.5M |
| Property and equipment, net | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M | $0.0M | $0.4M | $0.4M | $0.5M | $0.6M |
| Goodwill | — | $0.0M | $0.7M | $0.7M | — | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Intangible assets | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.8M | $1.4M | $3.0M | $1.9M |
| Total assets | $0.1M | $0.3M | $1.1M | $0.1M | $1.0M | $2.2M | $29.2M | $27.3M | $30.6M | $30.1M |
| Total liabilities | $0.3M | $0.8M | $1.2M | $0.8M | $2.0M | $2.0M | $7.6M | $6.1M | $7.1M | $7.0M |
| Preferred stock | $0.0M | $0.0M | — | — | $0.1M | $0.1M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | −$0.2M | −$0.6M | −$0.1M | −$0.7M | −$1.0M | $0.2M | $21.6M | $21.2M | $23.5M | $23.0M |
| Margins | ||||||||||
| Gross margin | — | — | — | 47.9% | 63.9% | 48.4% | 39.0% | 34.6% | 30.6% | 33.8% |
| Operating margin | — | — | — | −3,040.8% | −808.0% | −1,068.3% | −621.3% | −19.9% | −16.7% | −17.2% |
| EBITDA margin | — | — | — | −2,975.4% | −788.2% | −1,062.8% | −620.8% | −19.2% | −16.0% | −16.2% |
| Net margin | — | — | — | −7,868.7% | −3,899.3% | −5,445.0% | −615.4% | −18.7% | −14.7% | −16.5% |
| FCF margin | — | — | — | −2,354.0% | −922.3% | −800.8% | −125.2% | −36.8% | −40.7% | −15.2% |
| Returns | ||||||||||
| Return on capital employed | 473.6% | 173.7% | −497.4% | 87.2% | 9,946.6% | −115.6% | −121.0% | −22.0% | −24.0% | −26.3% |
| Return on equity | — | — | — | — | — | — | −244.9% | −21.0% | −23.0% | −25.7% |
| Return on assets | −5,429.7% | −646.3% | −307.1% | −266.8% | −486.9% | −765.7% | −170.1% | −15.9% | −17.7% | −19.7% |
| Return on tangible equity | — | — | — | — | — | −5,874.5% | −128.3% | −22.8% | −25.1% | −28.3% |
| Growth | ||||||||||
| Revenue growth | — | — | — | — | 238.4% | 219.9% | 1,802.6% | 454.4% | 44.7% | 4.1% |
| Share count change | — | — | — | — | — | — | 481.2% | −99.9% | 5,382.0% | — |
| Financial health | ||||||||||
| Interest coverage | −28.6x | −8.2x | −8.1x | −5.5x | −3.4x | −7.4x | −685.3x | −34.9x | −660.5x | — |
| Current ratio | 0.2x | 0.2x | 1.2x | 0.1x | 1.0x | 24.1x | 3.9x | 4.5x | 4.1x | 4.2x |
| Quick ratio | 0.2x | 0.2x | 1.2x | 0.1x | 1.0x | 22.9x | 3.5x | 3.5x | 2.3x | 2.1x |
| Capital allocation | ||||||||||
| Capex / revenue | — | — | — | 4.3% | 1.7% | 0.0% | 4.5% | 0.3% | 4.8% | 0.5% |
| Stock comp / revenue | — | — | — | 1,314.2% | 380.8% | — | — | — | — | — |
| Quality scores | ||||||||||
| Piotroski F-score | — | — | — | — | 4.0 | 3.0 | 3.0 | 4.0 | 1.0 | 4.0 |
| Altman Z'' | −763.1 | −211.7 | −50.6 | −675.6 | −67.4 | −49.4 | −5.3 | −0.5 | −0.9 | −1.6 |
| Accruals ratio | −4,941.8% | −308.6% | −234.1% | −187.1% | −371.9% | −653.1% | −136.7% | 15.1% | 25.5% | −2.1% |
Source: SEC EDGAR XBRL filings (CIK 0001402328). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.